DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer.
Ebata T, Yamashita S, Takeshima H, Yoshida H, Kawata Y, Kino N, Yasugi T, Terao Y, Yonemori K, Kato T, Ushijima T.
Gynecol Oncol. 2022 Oct 14:S0090-8258(22)01881-9. doi: 10.1016/j.ygyno.2022.10.008. Epub ahead of print.
Association of Treatment Response with Clinicopathological Characteristics in Female Breast Cancer Patients: Genomic Insights for Future Implementation of Personalized Medicine in Egypt.
Nakhla S, Elhameed AA, Ali IM, Elnaggar M, Hassan R, Yousef M, Adel K, Saleh W, Gaber M, Kotze MJ, El-Sharkawy RM.
Front Genet. 2022 Oct 12;12:990669. doi: 10.3389/fgene.2022.990669.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španic T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators.
Ann Oncol. 2022 Oct 10:S0923-7534(22)04165-5. doi: 10.1016/j.annonc.2022.09.159. Epub ahead of print.
PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment-A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters.
Stanowska O, Kuczkiewicz-Siemion O, Debowska M, Olszewski WP, Jagiello-Gruszfeld A, Tysarowski A, Prochorec-Sobieszek M.
Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
Huang TT, Burkett SS, Tandon M, Yamamoto TM, Gupta N, Bitler BG, Lee JM, Nair JR.
Oncogene. 2022 Oct 12. doi: 10.1038/s41388-022-02491-8. Epub ahead of print.
CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
Jacot W, Lusque A, Vicier C, Mailliez A, de La Motte Rouge T, Cabel L, Levy C, Patsouris A, Desmoulins I, Uwer L, Thery JC, Robain M, Caron O, Tredan O, Filleron T, Frenel JS, Delaloge S.
Br J Cancer. 2022 Oct 7. doi: 10.1038/s41416-022-02003-1. Epub ahead of print.
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D.
Cancer Treat Rev. 2022 Sep 28;111:102468. doi: 10.1016/j.ctrv.2022.102468. Epub ahead of print.